Cabozantinib for progressive metastatic medullary thyroid cancer: a review

References

• KloosRTEngCEvansDBFrancisGLAmerican Thyroid Association Guidelines Task ForceMedullary thyroid cancer: management guidelines of the American Thyroid AssociationThyroid20091956561219469690
   PubMed Web of Science ®Google Scholar
• HundahlSAFlemingIDFremgenAMA national cancer data base report on 53,856 cases of thyroid carcinoma treated in the US, 1985–1995Cancer199883263826489874472
   PubMed Web of Science ®Google Scholar
• DackiwAPThe surgical management of medullary thyroid cancerOtolaryngol Clin North Am20104336537420510719
   PubMed Web of Science ®Google Scholar
• VitaleGCaragliaMCiccarelliACurrent approaches and perspectives in the therapy of medullary thyroid carcinomaCancer2001911797180811335906
   PubMed Web of Science ®Google Scholar
• PinchotSNKunnimalaiyaanMSippelRSChenHMedullary thyroid carcinoma: targeted therapies and future directionsJ Oncol2009200918303120069043
   PubMedGoogle Scholar
• HartCDDe BoerRHProfile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancerOnco Targets Ther201361723319867
   PubMed Web of Science ®Google Scholar
• NagillaMBrownRLCohenEECabozantinib for the treatment of advanced medullary thyroid cancerAdv Ther20122992593423104465
   PubMed Web of Science ®Google Scholar
• CerratoADe FalcoVSantoroMMolecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targetsJ Mol Endocrinol20094314315519383830
   PubMed Web of Science ®Google Scholar
• MouraMMCavacoBMPintoAECorrelation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomasBr J Cancer20091001777178319401695
   PubMed Web of Science ®Google Scholar
• GiuntiSAntonelliAAmorosiASantarpiaLCellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinomaInt J Endocrinol2013201380317123509459
   PubMed Web of Science ®Google Scholar
• AlmeidaMQHoffAORecent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinomaCurr Opin Oncol20122422923422343387
   PubMed Web of Science ®Google Scholar
• RomanSMehtaPSosaJAMedullary thyroid cancer: early detection and novel treatmentsCurr Opin Oncol20092151019125012
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkClinical Practice Guidelines in Oncology: Thyroid Carcinoma, Version 22013
   Google Scholar
• WittRLWhat is the treatment of the lateral neck in clinically localized sporadic medullary thyroid cancer?Laryngoscope20101201286128720583117
   PubMed Web of Science ®Google Scholar
• RomanSLinRSosaJAPrognosis of medullary thyroid carcinoma; demographic, clinical, and pathologic predictors of survival 1252 casesCancer20061072134214217019736
   PubMed Web of Science ®Google Scholar
• BrierleyJShermanEThe role of external beam radiation and targeted therapy in thyroid cancerSemin Radiat Oncol20122225426222687950
   PubMed Web of Science ®Google Scholar
• MartinezSRBealSHChenAChenSLSchneiderPDAdjuvant external beam radiation for medullary thyroid carcinomaJ Surg Oncol201010217517820648590
   PubMed Web of Science ®Google Scholar
• SkouraEDepicting medullary thyroid cancer recurrence: the past and the future of nuclear medicine imagingInt J Endocrinol Metab201311e81561823853612
   PubMedGoogle Scholar
• Beuthien-BaumannBStrumpfAZessinJDiagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinomaEur J Nucl Med Mol Imaging2007341604160917435996
   PubMed Web of Science ®Google Scholar
• HoegerleSAltehoeferCGhanemN18F-DOPA positron emission tomography for tumour detection in patient with medullary thyroid carcinoma and elevated calcitonin levelsEur J Nucl Med200128647111202454
   PubMedGoogle Scholar
• KarrasSPontikidesNKrassasGEPharmacokinetic evaluation of cabozantinib for the treatment of thyroid cancerExpert Opin Drug Metab Toxicol2013950751523488614
   PubMed Web of Science ®Google Scholar
• KurzrockRShermanSIBallDWActivity of XL184 (cabozantinib), an oral tyrosine inhibitor, in patients with medullary thyroid cancerJ Clin Oncol2011292660266621606412
   PubMed Web of Science ®Google Scholar
• SenninoBIshiguro-OonumaTWeiYSuppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumorsCancer Discov2012227028722585997
   PubMed Web of Science ®Google Scholar
• YakesFMChenJTanJCabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growthMol Cancer Ther2011102298230821926191
   PubMed Web of Science ®Google Scholar
• BentzienFZuzowMHealdNIn vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in model of medullary thyroid carcinomaThyroid2013231569157723705946
   PubMed Web of Science ®Google Scholar
• SmithDCSmithMRSweeneyCCabozantinib in patients with advanced prostate cancer: results of a Phase II randomized discontinuation trialJ Clin Oncol20133141241923169517
   PubMed Web of Science ®Google Scholar
• Memorial Sloan-Kettering Cancer CenterCabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer Available from: http://clinicaltrials.gov/show/NCT01639508. NLM identifier: NCT01639508Accessed March 26, 2014
   Google Scholar
• DrilonAWangLHasanovicAResponse to cabozantinib in patients with RET fusion-positive lung adenocarcinomasCancer Discov2013363063523533264
   PubMed Web of Science ®Google Scholar
• SalgiaRHongDSCamachoLHA Phase I dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignanciesJ Clin Oncol200725Suppl 1814031
   Web of Science ®Google Scholar
• EliseiRSchlumbergerMJMüllerSPCabozantinib in progressive medullary thyroid cancerJ Clin Oncol2013313639364624002501
   PubMed Web of Science ®Google Scholar
• GoldenbergMMPharmaceutical approval updateP T201338869523599674
   PubMedGoogle Scholar
• RobinsonBGPaz-AresLKrebsAVasselliJHaddadRVandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancerJ Clin Endocrinol Metab2010952664267120371662
   PubMed Web of Science ®Google Scholar
• WellsSAJrRobinsonBGGagelRFVandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind Phase III trialJ Clin Oncol20123013414122025146
   PubMed Web of Science ®Google Scholar
• PerezCAArangoBAVelezMRaezLESantosESEmerging role of multikinase inhibitors for refractory thyroid cancerBiologics2012625726522904617
   PubMedGoogle Scholar
• LamETRingelMDKloosRTPhase II clinical trial of sorafenib in metastatic medullary thyroid cancerJ Clin Oncol2010282323233020368568
   PubMed Web of Science ®Google Scholar
• SchlumbergerMJEliseiRBastholtLPhase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancerJ Clin Oncol2009273794380119564535
   PubMed Web of Science ®Google Scholar
• GoulartBHCarrLLMankoffDAPhase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlationClin Cancer Res2010165260526820847059
   PubMed Web of Science ®Google Scholar
• CohenEERosenLSVokesEEAxitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a Phase II studyJ Clin Oncol20082823232330
   Google Scholar
• de GrootJWZonnenbergBAQuarles van Ufford-MannessePA Phase II trial of imatinib therapy for metastatic medullary thyroid carcinomaJ Clin Endocrinol Metab2007923466346917579194
   PubMed Web of Science ®Google Scholar
• Frank-RaueKFabelMDelormeSHaberkornURaueFEfficacy of imatinib mesylate in advanced medullary thyroid carcinomaEur J Endocrinol200715721522017656601
   PubMed Web of Science ®Google Scholar
• VerbeekHHAlvesMMde GrootJWThe effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cellsJ Clin Endocrinol Metab2011966E991E99521470995
   PubMed Web of Science ®Google Scholar
• BrassardMRondeauGRole of vandetanib in the management of medullary thyroid cancerBiologics20126596622500115
   PubMedGoogle Scholar
• ViolaDCappagliVEliseiRCabozantinib (XL 184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancerFuture Oncol2013981083109223902240
   PubMed Web of Science ®Google Scholar
• FaggianoARamundoVDicitoreAEverolimus is an active agent in medullary thyroid cancer: a clinical and in vitro studyJ Cell Mol Med2012161563157221883896
   PubMed Web of Science ®Google Scholar
• StarenkiDSinghNKJensenDRPetersonFCParkJIRecombinant leukemia inhibitory factor suppresses human medullary thyroid carcinoma cell line xenografts in miceCancer Lett201333914415123856028
   PubMed Web of Science ®Google Scholar
• SamadiAKBazzillJZhangXNovel withanolides target medullary thyroid cancer through inhibition of both RET phosphorylation and the mammalian target of rapamycin pathwaySurgery20121521238124723158190
   PubMed Web of Science ®Google Scholar
• CakirMGrossmanABMedullary thyroid cancer: molecular biology and novel molecular therapiesNeuroendocrinology20099032334819468197
   PubMed Web of Science ®Google Scholar